IFNA1 and B-cell chronic lymphocytic leukemia: Similar results were also observed using (i) healthy donor PBMCs as effectors, rather than CLL patient PBMCs (Supplementary Figure 5), and (ii) UV-inactivated reovirus or recombinant IFNα to activate NK cells and potentiate rituximab-mediated ADCC (Supplementary Figure 6).